These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21445714)

  • 1. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.
    Faggiano A; Di Somma C; Ramundo V; Severino R; Vuolo L; Coppola A; Panico F; Savastano S; Lombardi G; Colao A; Gasperi M
    Endocrine; 2011 Jun; 39(3):283-7. PubMed ID: 21445714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Alendronate increases bone mineral density in patients with symptomatic primary hyperparathyroidism].
    Misiorowski W
    Endokrynol Pol; 2005; 56(6):871-5. PubMed ID: 16821204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.
    Peacock M; Bilezikian JP; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E9-18. PubMed ID: 20943783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.
    Cesareo R; Di Stasio E; Vescini F; Campagna G; Cianni R; Pasqualini V; Romitelli F; Grimaldi F; Manfrini S; Palermo A
    Osteoporos Int; 2015 Apr; 26(4):1295-302. PubMed ID: 25524023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis.
    Rajput S; Dutta A; Rajender S; Mithal A; Chattopadhyay N
    Front Endocrinol (Lausanne); 2023; 14():1098841. PubMed ID: 36817591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].
    Arranz Martín A; Azcárate Villalón A; Luque Ramírez M; Santana Durán B; Marazuela Azpíroz M; Paniagua Ruiz A; Carraro R; Gómez Pan A
    Endocrinol Nutr; 2011 Jan; 58(1):24-31. PubMed ID: 21277266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism.
    Takeuchi Y; Takahashi S; Miura D; Katagiri M; Nakashima N; Ohishi H; Shimazaki R; Tominaga Y
    J Bone Miner Metab; 2017 Nov; 35(6):616-622. PubMed ID: 27873072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
    Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
    Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience.
    Manaka K; Sato J; Kinoshita Y; Ito N; Fujita M; Iiri T; Nangaku M; Makita N
    Endocr J; 2019 Aug; 66(8):683-689. PubMed ID: 31092749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling.
    Cetani F; Saponaro F; Banti C; Cianferotti L; Vignali E; Chiavistelli S; Viccica G; Pinchera A; Marcocci C
    J Endocrinol Invest; 2012 Jul; 35(7):655-60. PubMed ID: 21971564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.
    Iglesias P; Ais G; González A; Tajada P; García Arévalo C; Fernández Pardo E; Díez JJ
    Am J Med Sci; 2008 Feb; 335(2):111-4. PubMed ID: 18277118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.
    Khan A; Grey A; Shoback D
    J Clin Endocrinol Metab; 2009 Feb; 94(2):373-81. PubMed ID: 19193912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.
    Silverberg SJ; Rubin MR; Faiman C; Peacock M; Shoback DM; Smallridge RC; Schwanauer LE; Olson KA; Klassen P; Bilezikian JP
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3803-8. PubMed ID: 17666472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism.
    Bergua C; Torregrosa JV; Fuster D; Gutierrez-Dalmau A; Oppenheimer F; Campistol JM
    Transplantation; 2008 Aug; 86(3):413-7. PubMed ID: 18698244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
    Khan A; Bilezikian J; Bone H; Gurevich A; Lakatos P; Misiorowski W; Rozhinskaya L; Trotman ML; Tóth M
    Eur J Endocrinol; 2015 May; 172(5):527-35. PubMed ID: 25637076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinacalcet for the treatment of primary hyperparathyroidism.
    Dillon ML; Frazee LA
    Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ye Z; Silverberg SJ; Sreekanta A; Tong K; Wang Y; Chang Y; Zhang M; Guyatt G; Tangamornsuksun W; Zhang Y; Manja V; Bakaa L; Couban RJ; Brandi ML; Clarke B; Khan AA; Mannstadt M; Bilezikian JP
    J Bone Miner Res; 2022 Nov; 37(11):2351-2372. PubMed ID: 36053960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.
    Peacock M; Bilezikian JP; Klassen PS; Guo MD; Turner SA; Shoback D
    J Clin Endocrinol Metab; 2005 Jan; 90(1):135-41. PubMed ID: 15522938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet.
    Guerra R; Auyanet I; Fernández EJ; Pérez MÁ; Bosch E; Ramírez A; Suria S; Checa MD
    J Nephrol; 2011; 24(1):78-82. PubMed ID: 20437396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.